Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008

Psychiatric Services

Volumn 64, Issue 4, 2013, Pages 339-346

  Kornfield, Rachel ^a   Watson, Sydeaka ^b   Higashi, Ashley S ^c   Conti, Rena M ^b   Dusetzina, Stacie B ^d   Garfield, Craig F ^e   Dorsey, E Ray ^f   Huskamp, Haiden A ^g   Alexander, G Caleb ^h  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^d The University of North Carolina at Chapel Hill   (United States)

^e NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; CENTRAL STIMULANT AGENT; CLONIDINE; GUANFACINE; PSYCHOTROPIC AGENT;

ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL PRACTICE; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMATION DISSEMINATION; MEDICAL SPECIALIST; PHYSICIAN; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; PUBLIC HEALTH ADVISORY; TIME SERIES ANALYSIS; TREND STUDY;

ADOLESCENT; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADRENERGIC UPTAKE INHIBITORS; AMPHETAMINES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BUPROPION; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CLONIDINE; DOPAMINE UPTAKE INHIBITORS; DRUG UTILIZATION; GUANFACINE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PROPYLAMINES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84883127588     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201200147     Document Type: Article

References (40)

1. Leibson CL, Katusic SK, Barbaresi WJ, et al: Use and costs of medical care for children and adolescents with and without attention-deficit/ hyperactivity disorder. JAMA 285:60-66, 2001
2. Pelham WE, Foster EM, Robb JA: The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. Ambulatory Pediatrics 7(suppl): 121-131, 2007
3. Froehlich TE, Lanphear BP, Epstein JN, et al: Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children. Archives of Pediatrics and Adolescent Medicine 161:857-864, 2007
4. Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children-United States, 2003 and 2007. Morbidity and Mortality Weekly Report 59:1439-1443, 2010
5. Olfson M, Gameroff MJ, Marcus SC, et al: National trends in the treatment of attention deficit hyperactivity disorder. American Journal of Psychiatry 160:1071-1077, 2003
6. Zuvekas SH, Vitiello B: Stimulant medication use in children: A 12-year perspective. American Journal of Psychiatry 169: 160-166, 2012
7. Garfield CF, Dorsey ER, Zhu S, et al: Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000-2010. Academic Pediatrics 12:110-116, 2012
8. Zito JM, Safer DJ, DosReis S, et al: Psychotropic practice patterns for youth: A 10-year perspective. Archives of Pediatrics and Adolescent Medicine 157:17-25, 2003
9. Michelson D, Allen AJ, Busner J, et al: Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebocontrolled study. American Journal of Psychiatry 159:1896-1901, 2002
10. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al: Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial. Journal of the American Academy of Child and Adolescent Psychiatry 41:776-784, 2002
11. American Academy of Pediatrics, Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improve ment: Clinical practice guideline: Treatment of the school-aged child with attentiondeficit/ hyperactivity disorder. Pediatrics 108:1033-1044, 2001
12. Wolraich M, Brown L, Brown RT, et al: ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 128: 1007-1022, 2011
13. Wilens TE, Hammerness PG, Biederman J, et al: Blood pressure changes associated with medication treatment of adults with attention-deficit/ hyperactivity disorder. Journal of Clinical Psychiatry 66:253-259, 2005
14. Wooltorton E: Suicidal ideation among children taking atomoxetine (Strattera). Canadian Medical Association Journal 173:1447, 2005
15. Wernicke JF, Faries D, Girod D, et al: Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Safety 26:729-740, 2003
16. Nissen SE: ADHD drugs and cardiovascular risk. New England Journal of Medicine 354:1445-1448, 2006
17. Rapport MD, Moffitt C: Attention deficit/hyperactivity disorder and methylphenidate: A review of height/weight, cardiovascular, and somatic complaint side effects. Clinical Psychology Review 22:1107-1131, 2002
18. Findling RL, Biederman J, Wilens TE, et al: Short-and long-term cardiovascular effects of mixed amphetamine salts extended release in children. Journal of Pediatrics 147:348-354, 2005
19. Cooper WO, Habel LA, Sox CM, et al: ADHD drugs and serious cardiovascular events in children and young adults. New England Journal of Medicine 365: 1896-1904, 2011
20. Public Health Advisory for Adderall and Adderall XR. Silver Spring, Md, US Food and Drug Administration, Feb 9, 2005. Available at www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatients andProviders/ DrugSafetyInformationforHeath careProfessionals/PublicHealthAdvisories/ ucm051672.htm
21. Public Health Advisory: Suicidal Thinking in Children and Adolescents Being Treated With Strattera (Atomoxetine). Silver Spring, Md, US Food and Drug Administration, Sept 29, 2005. Available at www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafety InformationforPatientsandProviders/ DrugSafetyInformationforHeathcare Professionals/PublicHealthAdvisories/UCM051733
22. FDA Directs ADHD Drug Manufacturers to Notify Patients About Cardiovascular Adverse Events and Psychiatric Adverse Events. Silver Spring, Md, US Food and Drug Administration, Feb 21, 2007. Available at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108849.htm
23. Manual of Policies and Procedures: NDAs: "Dear Health Care Professional" Letters. Silver Spring, Md, US Food and Drug Administration, Center for Drug Evaluation and Research, July 7, 2003. Available at www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ManualofPolicies Procedures/ucm082012.pdf
24. American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD. Elk Grove Village, Ill, American Academy of Pediatrics, May 16, 2008. Available at www.aap.org/pressroom/aapahastatement. htm.
25. Vetter VL, Elia J, Erickson C, et al: Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder: A scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 117:2407-2423, 2008. Available at circ.ahajournals.org/cgi/content/full/117/18/ 2407.
26. Zell ER, McCaig LF, Kupronis BA, et al: A comparison of the National Disease and Therapeutic Index and the National Ambulatory Medical Care Survey to evaluate antibiotic usage; in Proceedings of the Survey Research Methods Section, American Statistical Association. Alexandria, Va, American Statistical Association, 2000. Available at www.amstat.org/sections/srms/Proceedings/papers/ 2000-143.pdf
27. Stafford RS, Radley DC: The underutilization of cardiac medications of proven benefit, 1990 to 2002. Journal of the American College of Cardiology 41:56-61, 2003
28. Higashi AS, Zhu S, Stafford RS, et al: National trends in ambulatory asthma treatment, 1997-2009. Journal of General Internal Medicine 26:1465-1470, 2011
29. Libby AM, Brent DA, Morrato EH, et al: Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. American Journal of Psychiatry 164:884-891, 2007
30. Nemeroff CB, Kalali A, Keller MB, et al: Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Archives of General Psychiatry 64:466-472, 2007
31. Majumdar SR, Almasi EA, Stafford RS: Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA 292:1983-1988, 2004
32. Graham DJ, Drinkard CR, Shatin D, et al: Liver enzyme monitoring in patients treated with troglitazone. JAMA 286:831-833, 2001
33. Kalra A, Li S, Zhang W: Understanding responses to contradictory information about products. Marketing Science 30:1098-1114, 2011
34. Willy ME, Manda B, Shatin D, et al: A study of compliance with FDA recommendations for pemoline (Cylert). Journal of the American Academy of Child and Adolescent Psychiatry 41:785-790, 2002
35. Dusetzina SB, Higashi AS, Dorsey ER, et al: Impact of FDA drug risk communications on health care utilization and health behaviors: A systematic review. Medical Care 50:466-478, 2012
36. Azoulay P: Do pharmaceutical sales respond to scientific evidence? Journal of Economics and Management Strategy 11: 551-594, 2002
37. Wagner AK, Soumerai SB, Zhang F, et al: Segmented regression analysis of interrupted time series studies in medication use research. Journal of Clinical Pharmacy and Therapeutics 27:299-309, 2002
38. Chintagunta PK, Jiang R, Jin GZ: Information, learning, and drug diffusion: The case of Cox-2 inhibitors. Quantitative Marketing and Economics 7:399-443, 2009
39. Szabo L: New warnings due for ADHD drugs. USA Today, June 30, 2005, p 1A
40. Thomas CP, Conrad P, Casler R, et al: Trends in the use of psychotropic medications among adolescents, 1994 to 2001. Psychiatric Services 57:63-69, 2006